Nuwellis Inc vs VanEck Semiconductor ETF — how do they compare? Nuwellis Inc trades at $1.4 (market cap $542.80K), while VanEck Semiconductor ETF trades at $586.39. The key difference: VanEck Semiconductor ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| NUWE | SMH | |
|---|---|---|
Market Cap | $542.80K | — |
Sector | Technology | — |
52-Week High | $220.50 | $668.91 |
52-Week Low | $1.42 | $286.43 |
Enterprise Value | -$1.27M | — |
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $1.43, up 0.7% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported a net loss of -$17.52M in 2025, with a negative net income margin of -217.22%, though recent news highlights product development and revenue growth initiatives, including a 14% preliminary year-over-year revenue increase in Q2 2026.
Outlook is cautious due to persistent losses and high cash burn, but growth in pediatric installations and strategic expansions offer potential. Risks include financial sustainability and competitive pressures, while analyst coverage is limited with a split buy/hold consensus.
SMH, the VanEck Semiconductor ETF, trades at $588.7, up 3.39% ($19.29) in the last session, with a bullish technical signal driven by moving averages. The ETF holds major semiconductor stocks but lacks disclosed financial ratios. Recent news highlights institutional buying, such as Ferguson Shapiro's $4.53 million investment (SEC filing, August 10, 2026), and mixed sentiment from analysts, including a downgrade to Hold by Seeking Alpha (August 10, 2026).
Outlook is cautiously optimistic, supported by AI-driven demand and global semiconductor initiatives, like South Korea's $3.52 billion fund (Reuters, August 10, 2026). Risks include tariff impacts from Trump's polysilicon policy and volatility from concentrated holdings. Investors should weigh growth potential against sector-specific headwinds.
Trailing returns across standard periods
Latest headlines on both assets
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →